6 Aug 20262cites
Time to Positivity of a Rapid HB s A g Assay as a Surrogate Marker of Quantitative HB s A g: Multicentre Proof‐of‐Concept StudyPublisher siteAlimentary Pharmacology & Therapeutics, Hepatitis B Virus Studies
Active, last published 2026
In cancer immunotherapy and biomarkers
Zelalem
Desalegn
Scholar“Research focused on Cancer Immunotherapy and Biomarkers and adjacent fields.”
Addis Ababa University
Ethiopia
Claim Your ProfileEthiopia15
H-index
505
Citations
Zelalem has not officially claimed their profile. If you are Zelalem, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
elalem Desalegn is a researcher working on Cancer Immunotherapy and Biomarkers. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Zelalem's work has been cited 505 times across 3 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Cancer Immunotherapy and Biomarkers×51Immunotherapy and Immune Responses×36Ferroptosis and cancer prognosis×18Cancer Genomics and Diagnostics×14Global Cancer Incidence and Screening×10
04 · Where I am
Affiliations
Affiliation on published researchAddis Ababa University, EthiopiaDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
8 works2 Dec 2024Open access
Blood immune profiling of Ethiopian patients with breast cancer highlights different forms of immune escapePublisher siteOncoImmunology, Cancer Immunotherapy and Biomarkers
25 Nov 2024Open access
Immune landscape of the tumour microenvironment in Ethiopian breast cancer patientsPublisher siteBreast Cancer Research, Cancer Immunotherapy and Biomarkers
11 Oct 2024Open access
Intrinsic Subtypes in Ethiopian breast cancer Patients: implications for better carePublisher siteInternational Journal of Cancer Care and Delivery, Global Cancer Incidence and Screening
9 Oct 2024Open access
Review of: "The In Vivo Erythrocyte Sedimentation Rate (ESR) Test: Pandemic Reemergence of Robin Fåhraeus’s “Fibrin Coagula”"Publisher site1 Nov 2023Open access7cites
Distribution of ß-Lactamase Genes Among Multidrug-Resistant and Extended-Spectrum ß-Lactamase-Producing Diarrheagenic Escherichia coli from Under-Five Children in EthiopiaPublisher siteInfection and Drug Resistance, Antibiotic Resistance in Bacteria
27 Jun 2023Open access25cites
High burden of ESBL and carbapenemase-producing gram-negative bacteria in bloodstream infection patients at a tertiary care hospital in Addis Ababa, EthiopiaPublisher sitePLoS ONE, Antibiotic Resistance in Bacteria
14 Apr 2023Open access21cites
Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan AfricaPublisher siteCancer Immunology Research, Cancer Immunotherapy and Biomarkers
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Zelalem?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you